Rigel Pharmaceuticals, Inc. (Rigel) is a clinical-stage drug development company that discovers and develops small molecule drugs for the treatment of inflammatory/autoimmune diseases, as well as for certain cancers and metabolic diseases. The Company's research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel has collaborations with pharmaceutical partners to develop and market its product candidates. The Company has internal product development programs in inflammatory/autoimmune diseases, such as rheumatoid arthritis, thrombocytopenia and asthma, as well as in cancer.